Search for neutral Higgs bosons in e
                $^+$
              e
                $^-$
               collisions at 
                $\sqrt{s}=183$
               GeV

al., P. Abreu et

doi:10.1007/s100529900111

Cited by 4 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our focus on comparing outcomes across 2 time periods—before and after widespread adoption of ICIs—mitigates concerns about patient-level confounding, as patient characteristics, such as comorbidity or performance status, are unlikely to change over such a short period . Fourth, it is important to note that approximately 50% of cases of advanced NSCLC express more than 1% PD-L1, and PD-L1 expression is associated with greater benefit from ICIs . Regular testing of PD-L1 expression started only partway through the study period and was therefore not included as a variable here.…”

Section: Discussionmentioning

confidence: 99%

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy

et al. 2023

View full text Add to dashboard Cite

ImportanceThe introduction of immune checkpoint inhibitors (ICIs) has transformed the care of advanced non–small cell lung cancer (NSCLC). Although clinical trials suggest substantial survival benefits, it is unclear how outcomes have changed in clinical practice.ObjectiveTo assess temporal trends in ICI use and survival among patients with advanced NSCLC across age strata.Design, Setting, and ParticipantsThis cohort study was performed in approximately 280 predominantly community-based US cancer clinics and included patients aged 18 years or older who had stage IIIB, IIIC, or IV NSCLC diagnosed between January 1, 2011, and December 31, 2019, with follow-up through December 31, 2020. Data were analyzed April 1, 2021, to October 19, 2022.Main Outcomes and MeasuresMedian overall survival and 2-year survival probability. The predicted probability of 2-year survival was calculated using a mixed-effects logit model adjusting for demographic and clinical characteristics.ResultsThe study sample included 53 719 patients (mean [SD] age, 68.5 [9.3] years; 28 374 men [52.8%]), the majority of whom were White individuals (36 316 [67.6%]). The overall receipt of cancer-directed therapy increased from 69.0% in 2011 to 77.2% in 2019. After the first US Food and Drug Administration approval of an ICI for NSCLC, the use of ICIs increased from 4.7% in 2015 to 45.6% in 2019 (P &lt; .001). Use of ICIs in 2019 was similar between the youngest and oldest patients (aged &lt;55 years, 45.2% vs aged ≥75 years, 43.8%; P = .59). From 2011 to 2018, the predicted probability of 2-year survival increased from 37.7% to 50.3% among patients younger than 55 years and from 30.6% to 36.2% in patients 75 years or older (P &lt; .001). Similarly, median survival in patients younger than 55 years increased from 11.5 months to 16.0 months during the study period, while survival among patients 75 years or older increased from 9.1 months in 2011 to 10.2 months in 2019.Conclusions and RelevanceThis cohort study found that, among patients with advanced NSCLC, the uptake of ICIs after US Food and Drug Administration approval was rapid across all age groups. However, corresponding survival gains were modest, particularly in the oldest patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In this case, the searches for visible and invisible Higgs bosons can be combined, and the excluded region in the (BR inv , m H ) plane is determined assuming SM production cross-sections. Using the DELPHI limits on the visible cross-section [17] a lower mass limit of 76.1 GeV/c 2 is found, independent of the fraction of invisible decays, as is apparent from figure 6b. In computing these limits, the overlap between the Standard Model Hν ν and the invisible Higgs boson hadronic selections have been resolved, by using only one at the time: the invisible hadronic mode in the region BR inv > 50%, and Hν ν in the region BR inv < 50%.…”

Section: Cross-section Limitmentioning

confidence: 62%

“…The event topology of the signal channel resembles the Hν ν channel analysed in [17], therefore similar event variables were used, except that no beauty flavour signature was required. The main kinematic variables are the estimated energy of a photon radiated in the beam direction E γ (normalized to the expected energy of a photon recoiling against a real Z), the total visible energy E vis , the thrust value in the rest system T r and the scaled acoplanarity log 10 θ acop .…”

Section: Particle and Event Selection Proceduresmentioning

confidence: 99%

A search for invisible Higgs bosons produced in e+e− interactions at LEP 2 energies

Abreu¹,

Adam

Adye

et al. 1999

Physics Letters B

View full text Add to dashboard Cite

“…The analysis of events with the Higgs produced in association with two electrons in DELPHI begins with the following preselection [47]. First, events with two oppositely charged electron candidates are identified.…”

Section: Two Jets and E + E − Or µ + µ −mentioning

confidence: 99%

“…To accept taus, events with exactly two jets, where both jets have three or fewer charged tracks and masses below 2 GeV/c 2 , are accepted [46]. For events not passing this selection for two taus, the event must have at least eight charged tracks, and the jet with the second highest energy must have at least two charged particles [47].…”

Section: Two Jets and E + E − Or µ + µ −mentioning

confidence: 99%

The Higgs particle in the standard model: experimental results from LEP

McNamara

2002

Rep. Prog. Phys.

View full text Add to dashboard Cite

At present, all the data obtained from the many experiments in particle physics are in agreement with the standard model. In the standard model there is one particle, the Higgs particle, that is responsible for giving masses to all particles with mass. In this sense, the Higgs particle occupies a unique position. Before the latter part of the year 2000, however, the Higgs particle was not observed experimentally. It is the purpose of this report to describe the first possible evidence for this particle, obtained by the four collaborations using the Large Electron-Positron colliding accelerator (LEP) at CERN, Geneva, Switzerland. The data were taken with the LEP centre-of-mass energy between 200 and 209 GeV. The result is dominated by the observation of an excess of four-jet events by ALEPH, one of the four experiments at LEP. Its mass, which is a free parameter in the standard model, is about 115 GeV/c 2 .

show abstract

Search for neutral Higgs bosons in e $^+$ e $^-$ collisions at $\sqrt{s}=183$ GeV

Cited by 4 publications

References 0 publications

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy

A search for invisible Higgs bosons produced in e+e− interactions at LEP 2 energies

The Higgs particle in the standard model: experimental results from LEP

Contact Info

Product

Resources

About